Fasudil
Idiopathic Pulmonary Fibrosis · ROCK Inhibition
Clinical trials
1
Mechanism
ROCK Inhibition
Developer
Japan Multi-center
Overview
Fasudil is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis, acting via rock inhibition. It appears in 1 tracked IPF clinical trial.
Fasudil clinical trials
Explore related
Medical disclaimer. This page summarizes research about Fasudil for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.